enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Numero di borse in cui sono quotate le azioni della società: 1. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'azienda
- Sito web
- engene.com
- Settore
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede centrale
- SAINT-LAURENT, Canada
- Amministratore delegato
- Mr. Ronald H. W. Cooper
- Dipendenti
- 81
- Azioni in circolazione
- 67.02 Mln al 2026-09-02
- Flottante
- 32.75 Mln
- Capitalizzazione di mercato
- 132.02 Mln USD
- Insider
- 0.11%
- Investitori istituzionali
- 84.11%
- Settore (SIC)
- Biological Products, (No Diagnostic Substances)
Descrizione
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Borse e ticker
| Borsa | Ticker | Valuta | Prezzo | Tipo |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.8 -3.74% | azioni ordinarie |
Dividendi
Nessun pagamento di dividendi trovato (controllato 07.10.2026). Probabilmente la società non distribuisce dividendi.
Notizie di questa settimana
Ancora nessuna notizia dal sito della società.
Principali azionisti
| Detentore | Quota | Azioni | Data del rapporto |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 Mln | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 Mln | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 Mln | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 Mln | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 Mln | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 Mln | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 Mln | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 Mln | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 Mln | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 Mln | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
